Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Cerevel Therapeutics to $26 from $28 and keeps a Neutral rating on the shares post the Q4 results. The analyst views the stock’s risk/reward as balanced.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CERE:
- Cerevel Therapeutics to Present at the 43rd Annual Cowen Health Care Conference
- Cerevel Therapeutics price target lowered to $45 from $48 at H.C. Wainwright
- Wells Fargo downgrades Cerevel on lack of catalysts until 2024
- Cerevel Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
- Cerevel Therapeutics reports Q4 EPS (59c), consensus (64c)
